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Introduction
Peritonitis due to the secondary spread of infections such as
appendicitis and diverticulitis, gastrointestinal perforations
such as those associated with gastroduodenal ulcer, and
hepatobiliary infections such as acute gallbladder inﬂam-
mation, cholangitis and liver abscess are intraperitoneal
infections, which are encountered at a high frequency in
general clinical settings. This section turns the spotlight on
anaerobic bacteria in these intraperitoneal infections,
referring to the clinical signiﬁcance as well as main diag-
nostic points and treatment options.
Signiﬁcance of anaerobic bacteria in intraperitoneal
infections
With regard to human intestinal bacteria, it is believed that
1014 colony forming units (cfu) of several hundreds of
bacterial species exist in 1 g of bacteria, and that 20–40%
of these species can be cultured using routine culture
methods [1]. Conversely, more than half of intestinal
bacteria are unknown and exist in the aseptic peritoneal
cavity beyond the intestinal tract wall which is only several
millimeters in thickness. Thus, it can be said that intestinal
bacteria form a wondrous world of their own.
Gastrointestinal perforation is the state in which intes-
tinal bacteria at the perforated site leak out freely into the
peritoneal cavity. In perforation of the large intestine par-
ticularly, a plurality of bacterial species are isolated from
ascites. The bacteria, once they have leaked out freely into
the free peritoneal cavity, transit to the bloodstream
within an extremely short time via the thoracic duct.
The frequencies of blood culture and endotoxin measure-
ment are not high in acute peritonitis, but it is a well-
established fact that acute peritonitis is a morbid condition
of sepsis. In other words, intestinal resident ﬂorae of the
perforated site are important targeted bacteria, and many
show mixed infections with anaerobic and aerobic bacteria.
The morbid condition can also involve polymicrobial
infections with 2–5 types of bacteria.
Apart from causative bacteria of speciﬁc infections,
such as Clostridium species, anaerobic bacteria, which
clearly hold the dominant position among intestinal bac-
teria, show weak pathogenicity as compared to aerobic
bacteria including Staphylococcus species and Escherichia
coli, and speciﬁc attention has not been paid to anaerobic
as compared to aerobic bacteria. The complicated nature of
anaerobic culture, and so on, have also interfered with
studies on these bacteria. In recent years, however, the
importance of anaerobic bacteria is also increasingly being
recognized with the increase in the number of patients
highly susceptible to infections. Moreover, anaerobic bac-
teria have gradually been recognized as an important
pathway for the spread of resistant bacteria, because these
bacteria (anaerobes) are dominant in the intestine.
Acute peritonitis
There are primary, secondary, acute, chronic, bacterial and
aseptic types of peritonitis. However, acute peritonitis
means intraperitoneal inﬂammation due to spread from
perforation or an inﬂammatory lesion of the gastrointesti-
nal tract, as with perforation of a gastric ulcer or with
appendicitis, indicating secondary peritonitis.
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Primary bacterial peritonitis
This type of peritonitis does not involve perforation of the
gastrointestinal tract, and is recognized in patients with
liver cirrhosis complicated by ascitic ﬂuid and in patients
on peritoneal dialysis. Intestinal bacteria including E. coli
and gram-positive cocci (Enterococcus species, Strepto-
coccus species, Staphylococcus species, etc.) are frequently
isolated from ascitic ﬂuid as single bacterial species.
However, it is rare for anaerobic bacteria to be isolated
from these ﬂuids partly because of the inﬂuence of oxygen
pressure in the local region (of ascites).
Secondary peritonitis
As causes of secondary peritonitis, perforation of the gas-
trointestinal tract due to peptic ulcer or the spread from
inﬂammatory lesions such as appendicitis and diverticuli-
tis, or due to injury, and so on have been enumerated. Each
has a characteristic underlying disease.
Isolates from ascites
With regard to isolates from secondary peritonitis (Fig. 1),
frequencies of isolation of anaerobic gram-negative bacilli
(including the Bacteroides fragilis group) and anaerobic
gram-positive cocci are high, and anaerobic bacteria
account for 58.8% of all bacteria. With regard to aerobic
bacteria, frequencies of isolation of E. coli, enterococci,
Klebsiella species, Streptococcus species, and so on are
high.
Details of the frequencies of isolation of anaerobic
bacteria from secondary peritonitis are shown in Fig. 2.
The frequency of isolation of gram-negative bacilli is as
high as 55.2%. With regard to bacterial species, the fre-
quency of isolation of the B. fragilis group including
B. fragilis, B. thetaiotaomicron, B. vulgatus, B. distasonis,
B. ovatus, B. uniformis, B. eggerthii, B. merdae, B. caccae
and B. stercoris, is highest (29.3%), followed by the fre-
quencies for Bilophila wadsworthia, Prevotella species,
and Fusobacterium species, in that order. With regard to
gram-positive cocci (27.7%), the frequency of isolation of
genus Anaerococcus including Anaerococcus prevotii is
highest, followed by Micromonas micros, and members of
Streptococcus species such as Streptococcus constellatus,
in that order. With regard to gram-positive bacilli (13.4%),
genus Eubacterium, Lactobacillus species and Clostridium
species are isolated, but the isolation frequencies are low.
The frequency of isolation of gram-negative cocci such as
those of Veillonella species is also as low, only 3.7%.
Characteristics of the isolates
The isolates are intestinal bacteria, which leak from the
perforated site, and reﬂect the intestinal resident ﬂora of the
site. Figures 3 and 4 show the frequencies of the isolates
according to sites of upper and lower gastrointestinal tract
perforations, respectively. The frequencies of isolation ofFig. 1 Isolates from secondary peritonitis
Fig. 2 Anaerobic bacteria isolated from secondary peritonitis
Fig. 3 Isolates from peritonitis due to upper gastrointestinal
perforation
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anaerobic gram-positive cocci and fungi, as well as aerobic
gram-positive cocci such as enterococci and Streptococcus
species, from upper gastrointestinal tract perforation sites
are high. Conversely, the frequencies of isolation of
anaerobic gram-negative bacilli, including the B. fragilis
group, and gram-negative bacilli, including E. coli, from
lower gastrointestinal tract perforation sites are high.
Approximately one quarter of patients with peritonitis
from a perforated gastroduodenal ulcer are negative for
ascitic ﬂuid bacteria. Even when the ascitic ﬂuid is positive
for bacteria, the incidence of infection with a single bac-
terial species is relatively high. The number of contami-
nating bacteria is also small. The frequencies of isolation of
aerobic gram-positive cocci and fungi are higher than those
with lower gastrointestinal tract perforation [2].
Almost all patients with colonic perforation are positive
for bacteria in ascitic ﬂuid. The frequencies of isolation of
gram-negative bacilli, including anaerobic bacteria from
the colonic perforation site, are high; approximately 80%
show polymicrobial infections involving at least two bac-
terial species. Moreover, the patients are likely to experi-
ence bacterial shock because the number of contaminating
bacteria is large. When the time course from perforation to
the surgery is long, the involvement of contaminating
bacteria is increased, regardless of the perforation site.
Main points of treatment
The main treatment points can be summarized as follows:
(1) surgery at the site of perforation, (2) cardio-hemody-
namic support, and (3) administration of appropriate anti-
bacterial drugs. Administration of antibacterial drugs is
supplementary.
In patients with high susceptibility to infections, e.g.,
those who are immunocompromised, culture and exami-
nation of ascitic ﬂuid collected during the surgery and drug
sensitivity tests are conducted, and when the results are
clariﬁed, sensitivity to the drugs used is conﬁrmed. In cases
in which drainage through a drain is continued and infec-
tions persists as well, bacteriological examination is con-
ducted, and the drugs used are switched to others on the
basis of the culture results. Considerable attention should
be paid to the condition following perforation-induced
peritonitis involving the lower gastrointestinal tract,
because infections with anaerobic bacteria (abscess for-
mation) may occur after a set period of time.
For perforation of the upper gastrointestinal tract, broad-
spectrum penicillins (including b-lactamase inhibitor
combination drugs) and ﬁrst- and second-generation
cephalosporins are recommended as treatment, since the
isolation rate of gram-positive cocci at the perforated site is
high. However, since anaerobic, as well as aerobic, bacteria
are isolated with a frequency of approximately 30%,
cephamycins (including the oxacephem) with antibacterial
activity against these bacteria are also recommended for
severe and immunocompromised cases. As compared to
other sites of perforation, the frequency of isolation of
fungi from this site (upper gastrointestinal tract) is high,
but it is not necessary to administer antifungal drugs from
the beginning of treatment.
The possibility of gram-negative bacilli and anaerobic
bacteria being involved in the mechanism of perforation of
the lower gastrointestinal tract is high. These bacteria are
often seen in polymicrobial infections. For these reasons,
drugs with antibacterial activity against these bacteria and
with a potent action against b-lactamase are recommended
as treatment [3, 4] (Table 1).
Hepatobiliary infections
Surgical treatment, including drainage under ultrasono-
graphic guidance, is frequently required for treatment of
hepatobiliary infections. An appropriate therapeutic
method had not been established until adoption of the
combined use of antibacterial drugs with surgical
treatment.
Acute cholecystitis and severe acute cholangitis
Etiology
Acute cholecystitis is a morbid condition in which the
cystic duct is occluded, for various reasons, leading to
elevated bile duct pressure. Approximately 90% of acute
cholecystitis cases show mechanical and chemical inﬂam-
mation attributable to occlusion of the cystic duct by cal-
culi. Essentially, bacterial infection is not involved in this
morbid condition from the beginning of its development.
However, when the condition is positive for bacteria in the
bile and calculi are impacted in the cystic duct, bacterial
Fig. 4 Isolates from peritonitis due to lower gastrointestinal
perforation
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infection manifests with the condition from the beginning
of its development, although the infection is secondary,
thereby leading to serious morbidity [5, 6].
Severe acute cholangitis (acute occlusive purulent cho-
langitis) is a morbid condition in which bile duct pressure
is elevated by stenosis of bile duct and bacteria in the bile,
as well as systemic endotoxin reﬂux via the liver and
hepatic veins (cholangiovenous reﬂux). Bacteria in the bile,
endotoxins, exotoxins, and/or bacterial metabolites are
involved in the morbid condition, and bacterial shock
ultimately develops leading to multiple organ failure.
Much attention should be paid to whether or not positive
biliary results for bacteria are obtained, because this con-
siderably impacts the morbid condition. Further attention
should be paid to changes in the severity as regards whether
or not the causative bacteria are potent and involved in
polymicrobial infections, and the numbers of these bacteria.
Isolates from biliary tract infections
With regard to isolates from biliary tract infections, the
frequency of isolation of enterococci is highest among
aerobic bacteria, followed by E. coli, Klebsiella species
Enterobacter species, and Pseudomonas aeruginosa, in
that order (Fig. 5). The rate of isolation of anaerobic bac-
teria from biliary tract infections is lower than that for
secondary peritonitis, but gram-negative bacilli including
the B. fragilis group are isolated [7].
Main points of treatment
Surgical treatment, including release of the occlusion and
drainage at the site, takes the highest priority, over other
procedures. It is not advisable to depend only on antibac-
terial drugs.
The use of oral antibacterial drugs is indicated in mild
cases, while injections are needed for severe cases.
Attention should be paid to the point that absorption
becomes uncertain when administering oral antibacterial
drugs.
The sites of infection include the walls of the gall-
bladder and bile duct, and it is important to maintain
blood concentrations in these sites. The morbid condition
of severe cholangitis is sepsis, and it is important to
maintain blood concentrations of antibacterial drugs.
When the biliary tract is occluded, transfer of a drug to
bile becomes extremely low. However, if the biliary tract
occlusion is released, drug transfer to bile will improve.
Therefore, drugs with favorable transfer to bile are
advantageous for treatment. However, drugs with potent
antibacterial activity against causative bacteria are also
efﬁcient for treatment, despite minimal transfer to bile.
Therefore, the antibacterial spectrum as well as anti-
bacterial activity should also be taken into consideration
[8, 9].
In general, drugs with potent antibacterial activity
against aerobic gram-negative bacilli, such as E. coli,
Klebsiella species, and Enterobacter species, are selected
Table 1 Selection of drugs used for treatment of peritonitis according to perforation sites
Upper gastrointestinal tract Broad-spectrum penicillins (including b-lactamase inhibitor combination drugs)
First- and second-generation cephalosporins
Cephamycins (including the oxa-type)
Lower gastrointestinal tract Cephamycins (including the oxa-type)
Carbapenems
Fluoroquinolones for injection
Second- to fourth-generation cephalosporins
b-lactamase inhibitor combination drugs (sulbactam/cefoperazone,
tazobactam/piperacillina)
When using second- to fourth-generation cephalosporins and ﬂuoroquinolones for injection, which have no antibacterial activity against
anaerobic bacteria, to treat severe cases and those with high susceptibility to infections, combined use with an anti-anaerobic drug such as
clindamycin or minocycline should be taken into consideration
a Tazobactam/piperacillin is included among the treatment indications, though this indication is not covered by medical insurance
Fig. 5 Isolates from primary biliary infections
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(Table 2). For severe cases, carbapenems with potent
antibacterial activities are also recommended, though
transfer to bile is minimal.
Liver abscess
Liver abscesses are divided into bacterial and amebic
types. Large abscesses need to be treated by surgical pro-
cedures such as drainage.
Many gram-negative bacilli including E. coli, Klebsiella
species, Enterobacter species, and P. aeruginosa can cause
bacterial liver abscess. Among anaerobic bacteria, genus
Bacteroides is frequently causative bacteria, but the fre-
quency of isolation of these bacteria is low. The majority of
cases show mixed infections. The drugs used for treatment
are cephamycins and penicillins with b-lactamase inhibi-
tors and penicillins, third-generation cephems, and carba-
penems, all of which are effective against anaerobic
bacteria.
In amebic liver abscess, Entamoeba histolytica enters
the portal vein through the wall of the intestinal tract
during the course of amebic dysentery to form a liver
abscess. Mixed infections with intestinal bacteria including
anaerobes are seen and must frequently be treated by
combining antibacterial drugs with other procedures.
Metronidazole and tinidazole are used to treat amebic
dysentery. Since these drugs exhibit favorable antibacterial
activity against anaerobic bacteria as well, drugs that cover
aerobic gram-negative bacilli should be taken into con-
sideration as other concomitant drugs. There are many
cases in which cephamycins and carbapenems are used
with another treatment procedure.
Selection of therapeutic drugs based on bacterial
isolation and drug sensitivity
Situation of isolation
In 64 of the 66 cases, in which B. fragilis was isolated from
(primary) infections in the gastroenterological surgery
ﬁeld, 175 strains were isolated as mixed infections. The
proportion of E. coli among these (175) strains was highest
(18.3%), followed by Enterococcus species (10.3%), and
others of Bacteroides species (9.7%), in that order (Fig. 6).
Members of Pseudomonas species, i.e., obligate aerobes,
have also been isolated, though in small numbers.
Drug sensitivity
Drug sensitivities, according to the bacteria isolated during
a recent 5-year period (between April 2000 and March
2005, by association for the study of the sensitivities of
isolates from surgical infections), are shown in Tables 3, 4,
5, 6 and 7.
Carbapenems exert the strongest antibacterial activity
against all bacteria.
It has been believed that the mechanism underlying
resistance of many anaerobes involves b-lactamase pro-
duction. The antibacterial activity of a b-lactamase inhibitor
combination, i.e., TAZ/PIPC, is much more potent than that
of PIPC. Other combination drugs, i.e., SBT/ABPC and
SBT/CPZ, are also useful. However, attention should be paid
to these combination drugs, because the daily dose of each
b-lactamase inhibitor combination drug is set at relatively
low levels in Japan. The second antibacterial drug with
excellent antibacterial activity is cephamycins, followed by
oxacephems and MINO, in that order. In recent years many
strains of theB. fragilis group have become resistant not only
to CEZ but also to new cephalosporins [10]. There are strains
Table 2 Selection of antibacterial drugs for treatment of acute
cholecystitis
Mild Fluoroquinolones for oral use
Cephems for oral use
Moderate Second-generation cephalosporins
Cephamycins (including the oxa-type)
Broad-spectrum penicillins (including b-lactamase
inhibitor combination drugs)
Severe Third- and fourth-generation cephalosporins
(including b-lactamase inhibitor combination drugs)
Cephamycins (including the oxa-type)
Carbapenems
Fluoroquinolones for injection
When using second- to fourth-generation cephalosporins and ﬂuoro-
quinolones for injection, which have no antibacterial activity against
anaerobic bacteria, for the treatment of severe cases and those with
high susceptibility to infections, combined use with an anti-anaerobic
drug such as clindamycin or minocycline should be taken into
consideration
Fig. 6 Bacteria isolated with B. fragilis (from primary infections)
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of this groupwhich reportedly producemetallo-b-lactamase,
though the number is small [11].
Selection of therapeutic drugs
The frequency of isolation of enterococci is high, but
enterococci are not regarded as targeted bacteria from
the beginning of treatment. Attention should be paid to
aerobic gram-negative bacilli such as E. coli and aerobic
gram-positive bacteria such as Staphylococcus aureus.
Since anaerobic bacteria (excluding Clostridium species)
exert weak pathogenicity, in a manner similar to that of
enterococci, it is uncommon for anaerobic bacteria to be
regarded as targeted species for empiric therapy from the
Table 3 Sensitivities of
Anaerococcus prevotii to
various antibacterial agents
Agents Number of
strains tested
MIC range
(lg/mL)
MIC (lg/mL)
50 80 90
Ampicillin 71 B0.063 to 4 1 2 2
Piperacillin 29 B0.063 to 64 16 16 32
Tazobactam/piperacillin 51 B0.063 to 32 16 32 32
Cefazolin 71 B0.063 to[128 64 128 128
Cefotiam 71 B0.063 to[128 64 128 128
Ceftazidime 71 B0.063 to[128 [128 [128 [128
Flomoxef 71 B0.063 to 32 8 16 16
Cefpirome 71 B0.063 to[128 128 [128 [128
Cefepime 71 B0.063 to[128 128 [128 [128
Imipenem 71 B0.063 to 16 1 4 4
Meropenem 71 B0.063 to 2 0.5 1 1
Vancomycin 71 B0.063 to 4 2 2 4
Teicoplanin 71 B0.063 to 2 0.25 0.5 0.5
Clindamycin 71 B0.063 to[128 0.25 0.5 1
Minocycline 71 B0.063 to 32 4 16 16
Ciproﬂoxacin 51 0.25 to 64 1 16 32
Levoﬂoxacin 71 B0.063 to[128 2 16 16
Fosfomycin 71 B0.063 to[128 32 64 64
Table 4 Sensitivities of
Micromonas micros to various
antibacterial agents
Agents Number of
strains tested
MIC range
(lg/mL)
MIC (lg/mL)
50 80 90
Ampicillin 53 B0.063 to 16 B0.063 B0.063 0.125
Piperacillin 18 B0.063 to 0.125 B0.063 B0.063 0.125
Tazobactam/piperacillin 44 B0.063 B0.063 B0.063 B0.063
Cefazolin 53 B0.063 to 2 B0.063 0.125 0.25
Cefotiam 53 B0.063 to 1 0.25 0.5 0.5
Ceftazidime 53 B0.063 to 16 0.5 1 2
Flomoxef 53 B0.063 to 0.5 B0.063 0.125 0.125
Cefpirome 53 B0.063 to 4 0.125 0.25 0.5
Cefepime 53 B0.063 to 8 0.25 0.25 1
Imipenem 53 B0.063 to 1 B0.063 0.125 0.125
Meropenem 53 B0.063 to 0.25 B0.063 B0.063 0.125
Vancomycin 53 0.25 to 2 1 1 2
Teicoplanin 53 B0.063 to 0.5 0.125 0.125 0.25
Clindamycin 53 B0.063 to 16 0.125 0.25 0.25
Minocycline 53 B0.063 to 2 B0.063 B0.063 0.25
Ciproﬂoxacin 44 0.25 to 16 0.5 4 8
Levoﬂoxacin 53 B0.063 to 8 0.5 4 4
Fosfomycin 53 B0.063 to[128 0.5 1 2
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beginning of treatment in all cases. The exceptions are
severe cases and those with high susceptibility to
infections.
The anaerobic bacteria, to which attention should be
paid in intraperitoneal infections, are the B. fragilis group.
Many anaerobic bacteria including these bacteria are
involved in mixed infections with E. coli and aerobic gram-
negative bacilli including Klebsiella species Attention
should be paid to this possibility when drugs are selected
for empiric therapy.
There are two types of Bacteroides species which are
predominant among anaerobic bacteria, the type sensitive
to CLDM and that resistant to CLDM. Therefore, drugs
should be used for infections with these bacteria after
clariﬁcation of sensitivity test results.
When using the second- to fourth-generation cephalo-
sporins with low antibacterial activity against anaerobic
bacteria and injectable quinolones in Western countries,
combined use with anti-anaerobic drugs such as injectable
metronidazole, which is not commercially available in
Japan, is recommended in Western countries. In Japan,
combined use with CLDM or MINO is recommended for
treating patients with high susceptibility to infections
instead of injectable metronidazole.
Table 5 Sensitivities of
Bacteroides fragilis to various
antibacterial agents
Agents Number of
strains tested
MIC range
(lg/mL)
MIC (lg/mL)
50 80 90
Piperacillin 76 0.25 to[128 4 128 [128
Tazobactam/piperacillin 99 B0.063 to[128 B0.063 0.25 1
Cefmetazole 152 0.25 to[128 4 8 16
Cefmenoxime 152 0.25 to[128 8 128 128
Latamoxef 152 0.125 to[128 1 16 32
Flomoxef 152 B0.063 to[128 1 16 64
Cefpirome 152 0.5 to[128 16 [128 [128
Cefepime 152 0.25 to[128 16 [128 [128
Imipenem 152 B0.063 to 64 0.125 0.5 2
Meropenem 152 B0.063 to[128 0.125 0.5 4
Sulbactam/cefoperazone 152 0.125 to[128 2 4 8
Clindamycin 152 B0.063 to[128 0.25 [128 [128
Minocycline 152 B0.063 to 16 4 4 8
Ciproﬂoxacin 99 2 to[128 8 32 32
Levoﬂoxacin 152 1 to 128 2 4 16
Table 6 Sensitivities of
Bacteroides thetaiotaomicron to
various antibacterial agents
Agents Number of
strains tested
MIC range
(lg/mL)
MIC (lg/mL)
50 80 90
Piperacillin 28 2 to[128 16 32 [128
Tazobactam/piperacillin 35 B0.063 to 16 1 2 8
Cefmetazole 59 1 to[128 16 32 64
Cefmenoxime 59 4 to[128 32 64 128
Latamoxef 59 1 to[128 16 64 128
Flomoxef 59 B0.063 to[128 8 32 128
Cefpirome 59 8 to[128 128 [128 [128
Cefepime 59 16 to[128 [128 [128 [128
Sulbactam/cefoperazone 59 B0.063 to 16 4 8 16
Imipenem 59 B0.063 to 4 0.25 0.5 1
Meropenem 59 B0.063 to 2 0.25 0.5 1
Clindamycin 59 B0.063 to[128 2 [128 [128
Minocycline 59 B0.063 to 8 2 4 4
Ciproﬂoxacin 35 4 to 128 16 32 64
Levoﬂoxacin 59 2 to[128 8 16 16
90 J Infect Chemother (2011) 17 (Suppl 1):84–91
123
The combined administration of aminoglycoside and
anti-anaerobic drug should also be taken into consideration
for the treatment of patients allergic to b-lactams.
B. wadsworthia is resistant to many drugs including
carbapenems, but no bacteria are resistant to CLDM. MINO
also exerts high antibacterial activity against bacteria.
Many anaerobic bacteria produce b-lactamase, and
b-lactamase inhibitor combination drugs exert high anti-
bacterial activity against these bacteria. Carbapenems,
cephamycins, oxacephems, and MINO also show excellent
antibacterial activity.
Conclusion
Anaerobic bacteria, which predominate among intestinal
bacteria, deserve considerable attention in patients with
high susceptibility to infections. Anaerobic bacteria are
considered to occupy an important position among the
intestinal bacterial ﬂora involved in transfer of drug resis-
tance, which includes b-lactamase production. Attention
should be paid to future trends in these bacteria, focusing
on both fundamental research and clinical observations.
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